Your browser doesn't support javascript.
loading
Differential phenotypic expression of a novel PDHA1 mutation in a female monozygotic twin pair.
Horga, Alejandro; Woodward, Catherine E; Mills, Alberto; Pareés, Isabel; Hargreaves, Iain P; Brown, Ruth M; Bugiardini, Enrico; Brooks, Tony; Manole, Andreea; Remzova, Elena; Rahman, Shamima; Reilly, Mary M; Houlden, Henry; Sweeney, Mary G; Brown, Garry K; Polke, James M; Gago, Federico; Parton, Matthew J; Pitceathly, Robert D S; Hanna, Michael G.
Affiliation
  • Horga A; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
  • Woodward CE; Neuromuscular Diseases Unit, Department of Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
  • Mills A; Neurogenetics Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
  • Pareés I; Area of Pharmacology, Department of Biomedical Sciences, School of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Spain.
  • Hargreaves IP; Sobell Department of Motor Neuroscience and Movement Disorders, UCL Queen Square Institute of Neurology, London, UK.
  • Brown RM; Neurometabolic Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
  • Bugiardini E; Oxford Medical Genetics Laboratories, The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Brooks T; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
  • Manole A; UCL Genomics, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Remzova E; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
  • Rahman S; Neurometabolic Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
  • Reilly MM; Metabolic Unit, Great Ormond Street Hospital for Children NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health, London, UK.
  • Houlden H; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
  • Sweeney MG; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
  • Brown GK; Neurogenetics Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
  • Polke JM; Oxford Medical Genetics Laboratories, The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Gago F; Neurogenetics Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
  • Parton MJ; Area of Pharmacology, Department of Biomedical Sciences, School of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Spain.
  • Pitceathly RDS; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
  • Hanna MG; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK. r.pitceathly@ucl.ac.uk.
Hum Genet ; 138(11-12): 1313-1322, 2019 Dec.
Article in En | MEDLINE | ID: mdl-31673819
ABSTRACT
Pyruvate dehydrogenase complex (PDC) deficiency caused by mutations in the X-linked PDHA1 gene has a broad clinical presentation, and the pattern of X-chromosome inactivation has been proposed as a major factor contributing to its variable expressivity in heterozygous females. Here, we report the first set of monozygotic twin females with PDC deficiency, caused by a novel, de novo heterozygous missense mutation in exon 11 of PDHA1 (NM_000284.3 c.1100A>T). Both twins presented in infancy with a similar clinical phenotype including developmental delay, episodes of hypotonia or encephalopathy, epilepsy, and slowly progressive motor impairment due to pyramidal, extrapyramidal, and cerebellar involvement. However, they exhibited clear differences in disease severity that correlated well with residual PDC activities (approximately 60% and 20% of mean control values, respectively) and levels of immunoreactive E1α subunit in cultured skin fibroblasts. To address whether the observed clinical and biochemical differences could be explained by the pattern of X-chromosome inactivation, we undertook an androgen receptor assay in peripheral blood. In the less severely affected twin, a significant bias in the relative activity of the two X chromosomes with a ratio of approximately 7525 was detected, while the ratio was close to 5050 in the other twin. Although it may be difficult to extrapolate these results to other tissues, our observation provides further support to the hypothesis that the pattern of X-chromosome inactivation may influence the phenotypic expression of the same mutation in heterozygous females and broadens the clinical and genetic spectrum of PDC deficiency.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Pyruvate Dehydrogenase Complex Deficiency Disease / Pyruvate Dehydrogenase (Lipoamide) / X Chromosome Inactivation / Mutation Type of study: Prognostic_studies Limits: Female / Humans / Male Language: En Journal: Hum Genet Year: 2019 Type: Article Affiliation country: United kingdom

Full text: 1 Database: MEDLINE Main subject: Pyruvate Dehydrogenase Complex Deficiency Disease / Pyruvate Dehydrogenase (Lipoamide) / X Chromosome Inactivation / Mutation Type of study: Prognostic_studies Limits: Female / Humans / Male Language: En Journal: Hum Genet Year: 2019 Type: Article Affiliation country: United kingdom